Building a Safer and Faster CAR: Seatbelts, Airbags, and CRISPR

https://doi.org/10.1016/j.bbmt.2017.10.017Get rights and content
Under a Creative Commons license
open archive

Abstract

Therapeutic T cell engineering has recently garnered widespread interest because of the success of CD19 chimeric antigen receptor (CAR) therapy. CARs are synthetic receptors for antigen that redirect the specificity and reprogram the function of the T cells in which they are genetically introduced. CARs targeting CD19, a cell surface molecule found in most leukemias and lymphomas, have yielded high remission rates in patients with chemorefractory, relapsed disease, including acute lymphoblastic leukemia, chronic lymphocytic leukemia, and non-Hodgkin lymphoma. The toxicities of this treatment include B cell aplasia, cytokine release syndrome (CRS), and neurotoxicity. Although reversible in most instances, these toxicities may require specific medical interventions, including transfer to intensive care to treat severe CRS. Guidelines for managing these toxicities are emerging. The recent report of a nonhuman primate model for CRS is poised to help advance the management of this syndrome. Finally, new engineering modalities, based on the use of targeted nucleases like CRISPR, may further enhance the efficacy and safety of CAR T cells.

Key Words

Chimeric antigen receptor T cells
CART
Immunotherapy
Adoptive T cell therapy
Adoptive immunotherapy
Hematopoietic stem cell transplantation
Cytokine release syndrome
Neurologic Toxicity

Cited by (0)

Financial disclosure: See Acknowledgments on page 30.